For the four key players in neuromodulation, Abbott Laboratories Inc., Medtronic PLC, Boston Scientific Corp. and rising star Nevro Corp., spinal cord stimulation (SCS) systems for chronic pain management are a key opportunity for growth. This message was conveyed clearly by the companies when they announced preliminary earnings results –highlighting the neuromodulation business as a growth area – at the JP Morgan Healthcare conference in San Francisco early January, and rang even louder just days later at the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas, where the firms presented the latest clinical findings from SCS trials. (Also see "Market Intel: Pain Management II: Competition Intensifies For Spinal Cord Stim Market's Big Three" - Medtech Insight, 23 May, 2017.)
Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry
The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.
More from Neurology
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.
Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.
The company is recalling Pipeline Vantage 021 and 027 models because they pose a higher than normal risk of failing to properly attach to blood vessel walls, which can cause thrombosis, stroke or death. The recall for 027 is a product removal and for 021 is an update to the instructions for use.
More from Device Area
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.